• News
  • SAN DIEGO
  • Law

Banyan Biomarkers licenses IP to Abbott

Banyan Biomarkers Inc., a company headquartered in Alachua, Fla. but with a growing presence in Carlsbad, has licensed its intellectual property related to traumatic brain injury (TBI) biomarkers to Abbott (NYSE: ABT) for assessment and verification. The terms of the agreement were not disclosed.

"Prior research has shown that protein markers are released in the bloodstream following a brain injury," said Jackson Streeter, CEO of Banyan Biomarkers. "Assessing these biomarkers is an important step forward in providing physicians with an objective test to evaluate patients who may have suffered a concussion."

Detecting concussions is often difficult because the physical damage may not be obvious. A CT scan is often normal and symptoms can be similar to those of other medical conditions. Failure to make a correct diagnosis may have serious implications for the patient. Research indicates that repetitive head injury may lead to chronic traumatic encephalopathy (CTE), which shares many features of Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS).

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Subscribe Today!